Q-omics provides the consensus-scored KLHL18 profile across patient tissues and cancer cell-line models. KLHL18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KLHL18 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, KLHL18 RNA expression shows 20,727 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where KLHL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL18 survival associations across molecular data types. KLHL18 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL18 RNA expression–survival associations across cancer types. High KLHL18 expression shows unfavorable associations in ACC, KICH, MESO, LIHC and SKCM, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KLHL18 RNA expression.
This table summarizes KLHL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL18 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, COAD, UCEC and CHOL. The LIHC box plot shows higher KLHL18 RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with KLHL18 in patient tissues and cancer cell lines. In patient samples, KLHL18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
